St.Shine Optical Co (1565) Fair Value & Analysis
Healthcare · TW · Market cap 4.7B TWD
Fair value as of: Jul 21, 2026
From 23 valuation models · updated 20 days ago
Share price −2.7% over the past month.
A solid business, screening 110% undervalued on our models.
What matters now
- The price is below even our cautious bear case (148.92 TWD). The market is more pessimistic than our downside scenario.
- Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 92.00 TWD – 318.93 TWD · fair‑value band 148.92 TWD – 248.20 TWD · the 94.40 TWD price screens below the 198.56 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
St.Shine Optical Co (1565) currently trades at 94.40 TWD, while our model-based Fair Value estimate is 198.56 TWD, implying the stock looks roughly 110.3% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, St.Shine Optical Co generated revenue of 3.9B TWD at a net margin of 9.0%. Revenue declined 19.0% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of 1.4B TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 148.92 TWD (bear case) to 248.20 TWD (bull case); at 94.40 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 110%, 1565 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: DCF Models (203.05 TWD) versus Asset-Based (87.06 TWD). Highest evidence: Growth DCF (80).
Notify me when 1565 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
St.Shine Optical Co.,Ltd., together with its subsidiaries, manufactures, sells, and trades contact lenses, optical lenses, and related products in Asia, Europe, America, and Taiwan. The company's product portfolio includes daily disposable, frequent replacement, color, and silicone hydrogel soft contact lens, as well as cast-molded soft contact lenses.
Full company description
St.Shine Optical Co.,Ltd., together with its subsidiaries, manufactures, sells, and trades contact lenses, optical lenses, and related products in Asia, Europe, America, and Taiwan. The company's product portfolio includes daily disposable, frequent replacement, color, and silicone hydrogel soft contact lens, as well as cast-molded soft contact lenses. It offers its products under the Ticon brand name. The company's products are used to correct vision defects, such as myopia, hyperopia, and astigmatism. It also provides consulting services. The company was formerly known as First Optical Co., Ltd. and changed its name to St.Shine Optical Co.,Ltd. in 1986. St.Shine Optical Co.,Ltd. was founded in 1981 and is headquartered in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
St.Shine Optical Co reported revenue of 4.1B TWD in FY2025 versus 5.4B TWD in FY2021, a compound −6.6%/yr. Reported net income was 455M TWD in FY2025, compounding −16.8%/yr from FY2021.
Watch 1565: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare St.Shine Optical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is St.Shine Optical Co (1565) overvalued or undervalued?
What is the fair value of 1565?
What is the quality score of 1565?
What is the revenue of St.Shine Optical Co (1565)?
What is the net profit margin of 1565?
Does St.Shine Optical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track St.Shine Optical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.